210 related articles for article (PubMed ID: 21713964)
21. A-methylacyl-CoA racemase (AMACR) and prostate-cancer risk: a meta-analysis of 4,385 participants.
Jiang N; Zhu S; Chen J; Niu Y; Zhou L
PLoS One; 2013; 8(10):e74386. PubMed ID: 24130666
[TBL] [Abstract][Full Text] [Related]
22. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Stewart J; Fleshner N; Cole H; Sweet J
J Clin Pathol; 2007 Jul; 60(7):773-80. PubMed ID: 16916997
[TBL] [Abstract][Full Text] [Related]
23. Semen AMACR protein as a novel method for detecting prostate cancer.
Etheridge T; Straus J; Ritter MA; Jarrard DF; Huang W
Urol Oncol; 2018 Dec; 36(12):532.e1-532.e7. PubMed ID: 30337219
[TBL] [Abstract][Full Text] [Related]
24. Alpha methylacyl-CoA racemase (AMACR) in prostate adenocarcinomas from Japanese patients: is AMACR a "race"-dependent marker?
Yamada H; Tsuzuki T; Maeda N; Yamauchi Y; Yoshida S; Ishida R; Nishikimi T; Yokoi K; Kobayashi H
Prostate; 2013 Jan; 73(1):54-9. PubMed ID: 22593005
[TBL] [Abstract][Full Text] [Related]
25. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
26. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
[TBL] [Abstract][Full Text] [Related]
27. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
28. Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Sroka WD; Adamowski M; Słupski P; Siódmiak J; Jarzemski P; Odrowąż-Sypniewska G; Marszałł MP
Int J Biol Markers; 2015 Nov; 30(4):e401-6. PubMed ID: 25982684
[TBL] [Abstract][Full Text] [Related]
29. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Jiang Z; Woda BA; Wu CL; Yang XJ
Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
[TBL] [Abstract][Full Text] [Related]
30. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia.
Wu CL; Yang XJ; Tretiakova M; Patton KT; Halpern EF; Woda BA; Young RH; Jiang Z
Hum Pathol; 2004 Aug; 35(8):1008-13. PubMed ID: 15297968
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of P504S/alpha-methylacyl-CoA racemase (AMACR) immunohistochemistry for the detection of prostate carcinoma on stored needle biopsies.
Vanguri VK; Woda BA; Jiang Z
Appl Immunohistochem Mol Morphol; 2006 Sep; 14(3):365-8. PubMed ID: 16932031
[TBL] [Abstract][Full Text] [Related]
32. α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC.
Xu B; Cai Z; Zeng Y; Chen L; Du X; Huang A; Liu X; Liu J
J Clin Pathol; 2014 Nov; 67(11):974-9. PubMed ID: 25092674
[TBL] [Abstract][Full Text] [Related]
33. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
34. Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy.
Magi-Galluzzi C; Luo J; Isaacs WB; Hicks JL; de Marzo AM; Epstein JI
Am J Surg Pathol; 2003 Aug; 27(8):1128-33. PubMed ID: 12883245
[TBL] [Abstract][Full Text] [Related]
35. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens.
Browne TJ; Hirsch MS; Brodsky G; Welch WR; Loda MF; Rubin MA
Hum Pathol; 2004 Dec; 35(12):1462-8. PubMed ID: 15619204
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of human α-methylacyl CoA racemase (AMACR): a target for prostate cancer.
Carnell AJ; Kirk R; Smith M; McKenna S; Lian LY; Gibson R
ChemMedChem; 2013 Oct; 8(10):1643-7. PubMed ID: 23929631
[TBL] [Abstract][Full Text] [Related]
37. Dietary influences on tissue concentrations of phytanic acid and AMACR expression in the benign human prostate.
Kataria Y; Wright M; Deaton RJ; Rueter EE; Rybicki BA; Moser AB; Ananthanrayanan V; Gann PH
Prostate; 2015 Feb; 75(2):200-10. PubMed ID: 25307752
[TBL] [Abstract][Full Text] [Related]
38. Tumor expression of adiponectin receptor 2 and lethal prostate cancer.
Rider JR; Fiorentino M; Kelly R; Gerke T; Jordahl K; Sinnott JA; Giovannucci EL; Loda M; Mucci LA; Finn S;
Carcinogenesis; 2015 Jun; 36(6):639-47. PubMed ID: 25863129
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic utility of alpha-methylacyl CoA racemase (P504S) on prostate needle biopsy.
Jiang Z; Woda BA
Adv Anat Pathol; 2004 Nov; 11(6):316-21. PubMed ID: 15505533
[TBL] [Abstract][Full Text] [Related]
40. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
Kunju LP; Chinnaiyan AM; Shah RB
Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
